GLP-1 Approval Guide: Medical Eligibility & Biomarker Insights

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medication approval typically requires documented type 2 diabetes, prediabetes, or obesity (BMI ≥30 kg/m²), along with baseline metabolic assessment and provider evaluation of overall health status. Approval pathways vary by geography, insurance coverage, and individual clinical presentation.

Understanding the clinical reasoning behind approval requirements—including metabolic markers, cardiovascular risk, and individual physiology—helps patients prepare meaningful conversations with healthcare providers. This precision-wellness approach moves beyond checkbox eligibility toward personalized treatment readiness.

Core Medical Eligibility Criteria for GLP-1 Approval

Approved indications include type 2 diabetes management, weight management in obesity, and cardiovascular risk reduction (depending on specific medication and indication). Most providers require documented baseline hemoglobin A1C, fasting glucose, lipid panel, and renal function before initiating therapy.

BMI thresholds typically start at 30 kg/m² for general obesity, or 27 kg/m² with comorbidities (hypertension, dyslipidemia, sleep apnea). Providers also assess medication history, contraindications, and personal or family history of thyroid disease or pancreatitis before approval.

Key Biomarkers and Lab Requirements Supporting Approval Decisions

Healthcare providers evaluate multiple biomarkers to establish baseline metabolic function and determine GLP-1 appropriateness. These markers inform both approval decisions and ongoing monitoring during treatment initiation and dose escalation.

Biomarker	Baseline Assessment & Clinical Significance
Hemoglobin A1C	Reflects 3-month average glucose; guides diabetes diagnosis and baseline severity (≥5.7% prediabetes, ≥6.5% diabetes)
Fasting Glucose	Immediate glucose status; values ≥100 mg/dL suggest impaired fasting glucose or diabetes
Lipid Panel (Total, LDL, HDL, Triglycerides)	Cardiovascular risk profile; elevated triglycerides or low HDL strengthen approval rationale
Creatinine & eGFR	Renal function assessment; dose adjustment or caution required if eGFR <30 mL/min/1.73m²
Liver Function Tests (ALT, AST)	Hepatic reserve and metabolic health; elevated transaminases may indicate NAFLD or other liver involvement
Fasting Insulin or HOMA-IR	Insulin resistance marker; elevated levels suggest metabolic dysfunction and GLP-1 benefit potential

The Provider Evaluation and Risk-Benefit Assessment

Approval is not automatic even when eligibility criteria are met. Providers conduct individualized risk-benefit analysis, examining personal and family history of medullary thyroid cancer (MTC), multiple endocrine neoplasia type 2 (MEN2), pancreatitis, and severe diabetic retinopathy.

Providers also consider concurrent medications (SGLT2 inhibitors, DPP-4 inhibitors), pregnancy status or planned pregnancy, and previous GLP-1 tolerance. This holistic evaluation ensures the chosen GLP-1 option aligns with individual physiology, comorbidities, and treatment goals.

Safety Considerations and Who Should Seek Provider Guidance First

Certain populations require enhanced medical oversight: those with severe renal impairment, acute pancreatitis history, diabetic retinopathy requiring ophthalmology management, or planned gastrointestinal surgery. Patients on insulin or with multiple comorbidities benefit from specialist coordination before initiating GLP-1.

Side effects including nausea, dehydration risk, and rare acute kidney injury or pancreatitis necessitate informed consent and follow-up monitoring. Providers establish baseline and follow-up schedules, typically reassessing metabolic markers at 3 months and annually, with closer monitoring during dose escalation phases.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by revealing predispositions in key peptide-signaling pathways—including GLP-1 receptor variants (rs6923761), GIPR variants (rs1800437), and MC4R/FTO variants affecting appetite regulation. These genetic insights should be interpreted with a qualified healthcare provider as part of comprehensive metabolic assessment, not as predictors of exact medication response.

The Precision Peptide Genetic Test examines genetic variation in peptide-signaling genes known to influence GLP-1 efficacy and metabolic phenotype. Understanding your genetic predisposition pattern can support more nuanced conversations with providers about treatment selection, expected response patterns, and personalized monitoring protocols during the approval and initiation process.

When combined with baseline biomarkers (A1C, lipid panel, insulin resistance markers) and clinical history, genetic predisposition data may help clarify why certain patients respond robustly to GLP-1 therapy while others show more modest effect. This information supports a more personalized approach to treatment planning and provider decision-making throughout the approval and ongoing care journey.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.